Can you provide the last earnings date for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) last reported earnings on 1/30/2026.
REGENERON PHARMACEUTICALS (REGN) Earnings History & Surprises
NASDAQ:REGN • US75886F1075
Current stock price
745.77 USD
-0.84 (-0.11%)
At close:
734.12 USD
-11.65 (-1.56%)
After Hours:
REGN Earnings overview
Past quarterly earnings results for REGENERON PHARMACEUTICALS (REGN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Apr 27, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $9.34
- Revenue Estimate
- 3.524B
Last Reported
Most Recent- Release Date
- Jan 30, 2026
- Period
- Q4 / 2025
- EPS Reported
- $11.44
- EPS Surprise
- 5.66%
- Revenue Surprise
- 0.21%
Beat Rate
Last 8 Quarters 63%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 11.44 | 10.83 | 5.66% | -5.22% | 3.884B | 3.876B | 0.21% | 2.51% |
| Q3 2025 | 11.83 | 9.78 | 20.96% | -5.06% | 3.754B | 3.657B | 2.66% | 0.90% |
| Q2 2025 | 12.89 | 8.61 | 49.77% | 11.51% | 3.676B | 3.35B | 9.72% | 3.62% |
| Q1 2025 | 8.22 | 9.00 | -8.66% | -13.93% | 3.029B | 3.34B | -9.31% | -3.69% |
| Q4 2024 | 12.07 | 11.50 | 4.93% | 1.77% | 3.789B | 3.824B | -0.91% | 10.34% |
| Q3 2024 | 12.46 | 11.93 | 4.48% | 7.51% | 3.721B | 3.744B | -0.62% | 10.65% |
| Q2 2024 | 11.56 | 10.83 | 6.79% | 12.89% | 3.547B | 3.446B | 2.93% | 12.32% |
| Q1 2024 | 9.55 | 10.29 | -7.23% | -5.35% | 3.145B | 3.284B | -4.23% | -0.54% |
| Q4 2023 | 11.86 | 10.95 | 8.36% | -5.57% | 3.434B | 3.351B | 2.48% | 0.57% |
| Q3 2023 | 11.59 | 10.93 | 6.01% | 4.04% | 3.363B | 3.298B | 1.96% | 14.53% |
| Q2 2023 | 10.24 | 10.04 | 1.99% | 4.81% | 3.158B | 3.077B | 2.64% | 10.53% |
| Q1 2023 | 10.09 | 9.75 | 3.50% | 12.99% | 3.162B | 3.06B | 3.34% | 6.64% |
| Q4 2022 | 12.56 | 10.23 | 22.77% | -41.09% | 3.414B | 3.188B | 7.10% | -31.05% |
| Q3 2022 | 11.14 | 9.67 | 15.25% | -22.48% | 2.936B | 2.926B | 0.35% | -14.96% |
| Q2 2022 | 9.77 | 9.02 | 8.33% | -62.13% | 2.857B | 2.852B | 0.18% | -44.40% |
| Q1 2022 | 8.93 | 9.93 | -10.09% | -9.71% | 2.965B | 2.779B | 6.70% | 17.26% |
| Q4 2021 | 21.32 | 18.71 | 13.93% | 123.71% | 4.952B | 4.598B | 7.69% | 104.37% |
| Q3 2021 | 14.37 | 10.31 | 39.43% | 71.89% | 3.453B | 2.873B | 20.18% | 50.51% |
| Q2 2021 | 25.80 | 17.88 | 44.32% | 260.34% | 5.139B | 3.995B | 28.62% | 163.24% |
| Q1 2021 | 9.89 | 9.18 | 7.72% | 49.85% | 2.529B | 2.602B | -2.82% | 38.32% |
| Q4 2020 | 9.53 | 8.56 | 11.32% | - | 2.423B | 2.471B | -1.95% | - |
| Q3 2020 | 8.36 | 7.28 | 14.87% | - | 2.294B | 2.13B | 7.70% | - |
| Q2 2020 | 7.16 | 6.10 | 17.32% | - | 1.952B | 1.777B | 9.85% | - |
| Q1 2020 | 6.60 | 6.25 | 5.53% | - | 1.828B | 1.793B | 1.96% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
16.93%
Max EPS beat (4)
49.77%
Min EPS beat (4)
-8.66%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
0.82%
Max Revenue beat (4)
9.72%
Min Revenue beat (4)
-9.31%
Analysis
In the last 4 quarters, REGN has beaten EPS estimates in 3 out of 4 releases
REGN has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, REGN has beaten the EPS estimates by 16.9% on average.
In the last 4 quarters, REGN has beaten the revenue estimates by 0.8% on average.
Related analysis
REGENERON PHARMACEUTICALS / REGN Earnings FAQ
Did REGENERON PHARMACEUTICALS (REGN) beat earnings estimates last quarter?
REGENERON PHARMACEUTICALS (REGN) beat EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often REGENERON PHARMACEUTICALS beats earnings estimates?
In the last 4 quarters, REGENERON PHARMACEUTICALS (REGN) has beaten EPS estimates in 3 out of 4 releases.